In this article, we described a second‐generation MAPK Adaptive Resistance Model (MARM2.0) that seeks to explain the rewiring of EGFR/MAPK signaling occurring in drug adapted BRAFV600E melanoma cells. Here, EGFR is linked to melanoma.